The potential for this novel Dox resistance mechanism to promote post-therapeutic relapse and metastatic progression in NBs expressing TrkAIII provides a rational for including approved Trk inhibitors, such as lestaurtinib, entrectinib, and crizotinib, during induction-phase chemotherapy with Dox. The gene discussed is NTRK1; the disease is Nijmegen breakage syndrome.